ANNOUNCEMENT OF CAPITAL MARKETS DAY
OSLO, NORWAY (November 8th, 2017) – NattoPharma is pleased to invite investors, media and others to a Capital Markets Day and business update to be held on December 5th, 2017.
The Capital Markets Day will be held in a central place in Oslo, and the venue for the event will be announced closer to the date. The event will start with registration and coffee at 9:30, and the presentation will start at 10:00, followed by a light lunch directly therafter.
If you would like to attend NattoPharmas CMD and business update, please register by email to CFO Kjetil Ramsøy, firstname.lastname@example.org, within December 1st, 2017.
The presentation will be held in English and will be published at approximately 9:30 the same day.
For more information, please contact:
Daniel H Rosenbaum, Kjetil Ramsøy,
This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 10:00 CET on November 8th, 2017.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending, and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.